Showing 6561-6570 of 8888 results for "".
- Skin Cancer Treatments, Cosmetic Procedures Lead Broad Practice Scope of ASDS Membershttps://practicaldermatology.com/news/20130226-skin_cancer_treatments_cosmetic_procedures_lead_broad_practice_scope_of_asds_members/2459607/The 2012 ASDS Survey on Dermatologic Procedures found that dermatologic surgeons performed nearly 8 million medically necessary and cosmetic procedures in the United States in 2012 (a nearly 7 percent increase over 2011), showcasing their extensive training and experience.
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatiti
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- FotoFinder Universe App Permits Image Access Via iPadhttps://practicaldermatology.com/news/20130215-fotofinder_universe_app_permits_image_access_via_ipad/2459614/Physicians can access before and after photos from an iPad for viewing, editing, and comparison, using FotoFinder's new Universe app for iPad 2, 3 and 4 and iPad mini. Used in conjunction with the company's mediscope photo documentation suite and Sate
- Red Alert: Rosacea Awareness Month Highlights Social Impact and Warning Signs of Rosaceahttps://practicaldermatology.com/news/20130215-red_alert_rosacea_awareness_month_highlights_social_impact_and_warning_signs_of_rosacea/2459615/According to a new patient survey conducted by the NRS, most rosacea patients feel the negative social impact of their condition regardless of which rosacea subtype they may have. While 61 percent of those with only subtype 1 (erythematotelangiectatic) ro
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs
- AADA Applauds Proposed Legislation to Repeal Medicare's IPABhttps://practicaldermatology.com/news/20130130-aada_applauds_proposed_legislation_to_repeal_medicares_ipab/2459624/The American Academy of Dermatology Association (AADA) issued a statement applauding the introduction of the Protecting Seniors' Access to Medicare Act, legislation that would repeal the Independent Payment Advisory Board (IPAB) created by the 2010 Affordable Care Act. The AADA argues that the IPAB